Cipla Ltd. — Regulatory Filings 2019

Sep 28, 2019

==> picture [99 x 39] intentionally omitted <==

28[th] September, 2019

BSE Ltd Listing Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

Scrip Code: 500087

National Stock Exchange of India Ltd Listing Department Exchange Plaza, 51h floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East}, Mumbai - 400 051 Scrip Code: CIPLA EQ

SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Dear Sir / Madam

Subject: USFDA cGMP inspection completed at Cipla's manufacturing facility in Goa

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at our Goa manufacturing facility from September 16-27, 2019.

The inspection ended with 12 observations, none of which are related to data integrity. The Company will respond to the agency within the stipulated timeline.

Kindly take the above information on record.

Thanking you,

Yours faithfully, For Cipla Limited

==> picture [84 x 59] intentionally omitted <==

Rajendra Chopra Company Secretary

Prepared by: Mandar Kurghode

==> picture [437 x 34] intentionally omitted <==